PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16149867

FDA perspectives on pharmacogenetic testing.

Courtney C Harper·Reena Philip·Max Robinowitz·Steven I Gutman
View original source ↗Export metadata ↓

Abstract

The field of pharmacogenetic testing is emerging as a topic of interest for many, due to its potential to improve patient care and optimize therapeutic development. The US Food and Drug Administration is interested in incorporating pharmacogenetics into development activities whenever appropriate to protect and promote public health. This article is intended to reflect the opinions of the Office of In vitro Diagnostic Device Evaluation and Safety in the Center for Devices and Radiological Health on some issues associated with developing in vitro diagnostic devices for use in pharmacogenetics. General points and potential issues related to the analytical and clinical validation of these types of devices will be discussed.

Explore related subjects

HealthHumansPharmacogeneticsUnited StatesUnited States Food and Drug AdministrationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Courtney C Harper, Reena Philip, Max Robinowitz, Steven I Gutman. 2005. FDA perspectives on pharmacogenetic testing.. https://doi.org/10.1586/14737159.5.5.643

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Sunlight, skin cancer and vitamin D: What are the conclusions of recent findings that protection against solar ultraviolet (UV) radiation causes 25-hydroxyvitamin D deficiency in solid organ-transplant recipients, xeroderma pigmentosum, and other risk groups?

A connection between vitamin D deficiency and severe health problems including various types of cancer has been demonstrated. We have shown that patients that have to protect themselves against solar UV radiation for medical reasons, including patients with xeroderma pigmentosum (XP), basal cell nevus syndrome (BCNS), lupus erythematodes (LE) or transplant recipients, are at risk to develop vitamin D deficiency. We conclude that 25-hydroxyvitamin D serum levels as a measure of vitamin D status have to be analyzed in patients that have to protect themselves against solar UV radiation for medical reasons. Suboptimal vitamin D status has to be substituted (e.g. via oral treatment) to protect against serious vitamin D deficiency-related health problems without increasing the risk to develop solar UV-induced skin cancer. Our finding that protection against solar UV radiation causes vitamin D deficiency underlines the need for re-defining dermatological recommendations for solar UV protection in skin cancer prevention programs.

Health↗
PubMed2006

What is health?

Explore the source record for details and available documents.

Health↗